Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors (Q33876683)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors (English)

1 reference

Europe PubMed Central

29 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

6

object named as

Hugues Charest

1 reference

Europe PubMed Central

29 July 2017

8

object named as

Michel Roger

1 reference

Europe PubMed Central

29 July 2017

Robert W Shafer

9

object named as

Robert Shafer

1 reference

Europe PubMed Central

29 July 2017

7

object named as

Bluma Brenner

1 reference

Europe PubMed Central

29 July 2017

2

object named as

Philip Grant

1 reference

Europe PubMed Central

29 July 2017

4

object named as

Jean-Guy Baril

1 reference

Europe PubMed Central

29 July 2017

author name string

Annie Talbot

1

1 reference

Europe PubMed Central

29 July 2017

Jonathan Taylor

3

1 reference

Europe PubMed Central

29 July 2017

Tommy Fulisma Liu

5

1 reference

Europe PubMed Central

29 July 2017

Régis Cantin

10

1 reference

Europe PubMed Central

29 July 2017

Andrew Zolopa

11

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

5 April 2010

1 reference

Europe PubMed Central

29 July 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

29 July 2017

54

1 reference

Europe PubMed Central

29 July 2017

6

1 reference

Europe PubMed Central

29 July 2017

2473-2479

1 reference

Europe PubMed Central

29 July 2017

Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

5 July 2018

Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

5 July 2018

Update of the Drug Resistance Mutations in HIV-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

5 July 2018

Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

5 July 2018

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

5 July 2018

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

5 July 2018

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

5 July 2018

Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

5 July 2018

Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

5 July 2018

HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

5 July 2018

Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

5 July 2018

Human immunodeficiency virus reverse transcriptase and protease sequence database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

5 July 2018

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

5 July 2018

Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

29 October 2018

The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

29 October 2018

Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2876425

29 October 2018

Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20368406

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20368406

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20368406

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20368406

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.00096-10

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33876683&oldid=1953577447"